Figure 5From: Phase II clinical trial of whole-brain irradiation plus three-dimensional conformal boost with concurrent topotecan for brain metastases from lung cancerThe 1- and 2-year extracranial lesion control rates of CRT and RT groups were 8 months, 47.8%, and 28.7% and 5 months, 32.5%, and 24.4% (χ2 = 0.610, p = 0.435), respectively.Back to article page